Remix Therapeutics disclosed the initial signs of tumor shrinkage in a patient with a rare salivary gland cancer treated with its small‑molecule mRNA degrader platform. The company reported early clinical activity in an indication where therapeutic options are limited, marking a translational milestone for small molecules that destabilize oncogenic mRNAs rather than inhibiting encoded proteins. Remix characterized the result as an initial proof‑of‑concept and said it will expand dosing cohorts to assess durability, response rates and safety. Investors and partners will watch for confirmation in additional patients and indications.